Press Resease

Lung Cancer Therapeutics Market By Cancer Type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), By Treatment (Immunotherapy, Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), By Drug Class (Antimetabolites, Alkylating Agents, Mitotic Inhibitors, EGFR Inhibitors, Multikinase Inhibitors, and Others), By End-User (Hospitals, Homecare, Specialty Clinics, and Others), and By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Internet, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 23-Aug-2019 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-4617 Status : Published

Global lung cancer therapeutics market expected to generate around USD 42.24 billion by 2025, growing at a CAGR of around 13.2% between 2019 and 2025. Cancer is a disease caused by an uncontrolled division of abnormal cells in part of the body. These extra cells slowly gather together to form a tissue mass called a tumor.

Description

The report covers a forecast and an analysis of the lung cancer therapeutics market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes the drivers and restraints of the lung cancer therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the lung cancer therapeutics market on a global and regional level.

In order to give the users of this report a comprehensive view of the lung cancer therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Lung Cancer Therapeutics Market

The report provides company market share analysis to give a broader overview of the key players in the lung cancer therapeutics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the lung cancer therapeutics market on a global and regional basis.

The global lung cancer therapeutics market is segmented based on cancer type, treatment, drug class, end-user, distribution channel, and region. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some key players in the lung cancer therapeutics market are Hoffmann-La Roche, Eli Lilly and Company, Sanofi-Aventis, Pfizer, Celgene Corporation, GlaxoSmithKline, Boehringer Ingelheim, Agennix, AstraZeneca, and Merck & Co.

This report segments the global Lung cancer therapeutics market into:

Global Lung Cancer Therapeutics Market: By Cancer Type

  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)

Global Lung Cancer Therapeutics Market: By Treatment

  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Others

Global Lung Cancer Therapeutics Market: By Drug Class

  • Antimetabolites
  • Alkylating Agents
  • Mitotic Inhibitors
  • EGFR Inhibitors
  • Multikinase Inhibitors
  • Others

Global Lung Cancer Therapeutics Market: By End-User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Global Lung Cancer Therapeutics Market: By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Internet
  • Others

Global Lung Cancer Therapeutics Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Lung Cancer Therapeutics Market Revenue, 2016-2025 (USD Billion)
    • 2.2. Global Lung Cancer Therapeutics Market: Snapshot
  •  
  • Chapter 3. Lung Cancer Therapeutics Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Lung Cancer Therapeutics Market Drivers: Impact Analysis
      • 3.2.2. Increasing Prevalence of Lung Cancer
      • 3.2.3. Increasing adoption of targeted therapies
    • 3.3. Market restraints
      • 3.3.1. High capital investments
    • 3.4. Opportunities
      • 3.4.1. Emerging markets
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Cancer Type
      • 3.6.2. Market attractiveness analysis, by Treatment
      • 3.6.3. Market attractiveness analysis, by Drug Class
      • 3.6.4. Market attractiveness analysis, by End-User
      • 3.6.5. Market attractiveness analysis, by Distribution Channel
      • 3.6.6. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Lung Cancer Therapeutics Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Lung Cancer Therapeutics Market: Company Market Share, 2018
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
  •  
  • Chapter 5. Global Lung Cancer Therapeutics Market - Cancer Type Analysis
    • 5.1. Global Lung Cancer Therapeutics Market: Cancer Type Overview
      • 5.1.1. Global Lung Cancer Therapeutics Market Share, by Cancer Type, 2018 and 2025
    • 5.2. Non-Small Cell Lung Cancer
      • 5.2.1. Global Lung Cancer Therapeutics Market for Non-Small Cell Lung Cancer, 2016-2025 (USD Billion)
    • 5.3. Small Cell Lung Cancer
      • 5.3.1. Global Lung Cancer Therapeutics Market for Small Cell Lung Cancer, 2016-2025 (USD Billion)
  •  
  • Chapter 6. Global Lung Cancer Therapeutics Market - Treatment Analysis
    • 6.1. Global Lung Cancer Therapeutics Market: Treatment overview
      • 6.1.1. Global Lung cancer therapeutics Market Share, by Treatment, 2018 and 2025
    • 6.2. Immunotherapy
      • 6.2.1. Global Lung cancer therapeutics market for Immunotherapy, 2016-2025 (USD Billion)
    • 6.3. Chemotherapy
      • 6.3.1. Global Lung cancer therapeutics market for Chemotherapy, 2016-2025 (USD Billion)
    • 6.4. Targeted Therapy
      • 6.4.1. Global Lung cancer therapeutics market for Targeted Therapy, 2016-2025 (USD Billion)
    • 6.5. Radiation Therapy
      • 6.5.1. Global Lung cancer therapeutics market for Radiation Therapy, 2016-2025 (USD Billion)
    • 6.6. Others
      • 6.6.1. Global Lung cancer therapeutics market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 7. Global Lung Cancer Therapeutics Market - Drug Class Analysis
    • 7.1. Global Lung Cancer Therapeutics Market: Drug Class Overview
      • 7.1.1. Global Lung cancer therapeutics Market Share, by Drug class, 2018 and 2025
    • 7.2. Antimetabolites
      • 7.2.1. Global Lung cancer therapeutics market for Antimetabolites, 2016-2025 (USD Billion)
    • 7.3. Alkylating Agents
      • 7.3.1. Global Lung cancer therapeutics market for Alkylating Agents, 2016-2025 (USD Billion)
    • 7.4. Mitotic Inhibitors
      • 7.4.1. Global Lung Cancer Therapeutics Market for Mitotic Inhibitors, 2016-2025 (USD Billion)
    • 7.5. EGFR Inhibitors
      • 7.5.1. Global Lung Cancer Therapeutics Market for EGFR Inhibitors, 2016-2025 (USD Billion)
    • 7.6. Multikinase Inhibitors
      • 7.6.1. Global Lung Cancer Therapeutics Market for Multikinase Inhibitors, 2016-2025 (USD Billion)
    • 7.7. Others
      • 7.7.1. Global Lung cancer therapeutics market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 8. Global Lung Cancer Therapeutics Market - End-User Analysis
    • 8.1. Global Lung Cancer Therapeutics Market: End-User overview
      • 8.1.1. Global Lung cancer therapeutics Market share, by End-User, 2018 and 2025
    • 8.2. Hospitals
      • 8.2.1. Global Lung Cancer Therapeutics Market for Hospitals, 2016-2025 (USD Billion)
    • 8.3. Homecare
      • 8.3.1. Global Lung Cancer Therapeutics Market for Homecare, 2016-2025 (USD Billion)
    • 8.4. Specialty Clinics
      • 8.4.1. Global Lung Cancer Therapeutics Market for Specialty Clinics, 2016-2025 (USD Billion)
    • 8.5. Others
      • 8.5.1. Global Lung Cancer Therapeutics Market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 9. Global Lung Cancer Therapeutics Market - Distribution Channel Analysis
    • 9.1. Global Lung Cancer Therapeutics Market: Distribution Channel overview
      • 9.1.1. Global Lung cancer therapeutics Market share, by Distribution Channel, 2018 and 2025
    • 9.2. Retail Pharmacy
      • 9.2.1. Global Lung Cancer Therapeutics Market for Retail Pharmacy, 2016-2025 (USD Billion)
    • 9.3. Hospital Pharmacy
      • 9.3.1. Global Lung Cancer Therapeutics Market for Hospital Pharmacy, 2016-2025 (USD Billion)
    • 9.4. Internet
      • 9.4.1. Global Lung cancer therapeutics market for Internet, 2016-2025 (USD Billion)
    • 9.5. Others
      • 9.5.1. Global Lung cancer therapeutics market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 10. Global Lung Cancer Therapeutics Market - Regional Analysis
    • 10.1. Global Lung Cancer Therapeutics Market: Regional overview
      • 10.1.1. Global Lung cancer therapeutics market share, by Region, 2018 and 2025
    • 10.2. North America
      • 10.2.1. North America Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
      • 10.2.2. North America Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
      • 10.2.3. North America Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
      • 10.2.4. North America Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
      • 10.2.5. North America Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.2.6. The U.S.
        • 10.2.6.1. The U.S. Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.2.6.2. The U.S. Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.2.6.3. The U.S. Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.2.6.4. The U.S. Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.2.6.5. The U.S. Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.2.7. Rest of North America
        • 10.2.7.1. Rest of North America Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.2.7.2. Rest of North America Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.2.7.3. Rest of North America Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.2.7.4. Rest of North America Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.2.7.5. Rest of North America Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
    • 10.3. Europe
      • 10.3.1. Europe Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
      • 10.3.2. Europe Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
      • 10.3.3. Europe Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
      • 10.3.4. Europe Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
      • 10.3.5. Europe Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.3.6. Germany
        • 10.3.6.1. Germany Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.3.6.2. Germany Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.3.6.3. Germany Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.3.6.4. Germany Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.3.6.5. Germany Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.3.7. The U.K.
        • 10.3.7.1. U.K. Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.3.7.2. U.K. Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.3.7.3. U.K. Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.3.7.4. U.K. Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.3.7.5. U.K. Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.3.8. France
        • 10.3.8.1. France Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.3.8.2. France Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.3.8.3. France Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.3.8.4. France Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.3.8.5. France Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.3.9. Rest of Europe
        • 10.3.9.1. Rest of Europe Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.3.9.2. Rest of Europe Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.3.9.3. Rest of Europe Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.3.9.4. Rest of Europe Lung cancer therapeutics market End-User, by End-User, 2016-2025 (USD Billion)
        • 10.3.9.5. Rest of Europe Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
    • 10.4. Asia Pacific
      • 10.4.1. Asia Pacific Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
      • 10.4.2. Asia Pacific Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
      • 10.4.3. Asia Pacific Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
      • 10.4.4. Asia Pacific Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
      • 10.4.5. Asia Pacific Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.4.6. China
        • 10.4.6.1. China Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.4.6.2. China Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.4.6.3. China Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.4.6.4. China Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.4.6.5. China Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.4.7. Japan
        • 10.4.7.1. Japan Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.4.7.2. Japan Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.4.7.3. Japan Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.4.7.4. Japan Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.4.7.5. Japan Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.4.8. India
        • 10.4.8.1. India Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.4.8.2. India Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.4.8.3. India Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.4.8.4. India Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.4.8.5. India Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.4.9. Rest of Asia Pacific
        • 10.4.9.1. Rest of Asia Pacific Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.4.9.2. Rest of Asia Pacific Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.4.9.3. Rest of Asia Pacific Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.4.9.4. Rest of Asia Pacific Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.4.9.5. Rest of Asia Pacific Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
    • 10.5. Latin America
      • 10.5.1. Latin America Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
      • 10.5.2. Latin America Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
      • 10.5.3. Latin America Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
      • 10.5.4. Latin America Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
      • 10.5.5. Latin America Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.5.6. Brazil
        • 10.5.6.1. Brazil Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.5.6.2. Brazil Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.5.6.3. Brazil Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.5.6.4. Brazil Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.5.6.5. Brazil Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
      • 10.5.7. Rest of Latin America
        • 10.5.7.1. Rest of Latin America Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
        • 10.5.7.2. Rest of Latin America Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
        • 10.5.7.3. Rest of Latin America Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 10.5.7.4. Rest of Latin America Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
        • 10.5.7.5. Rest of Latin America Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
    • 10.6. The Middle East and Africa
      • 10.6.1. The Middle East and Africa Lung cancer therapeutics market revenue, by Cancer Type, 2016-2025 (USD Billion)
      • 10.6.2. The Middle East and Africa Lung cancer therapeutics market revenue, by Treatment, 2016-2025 (USD Billion)
      • 10.6.3. The Middle East and Africa Lung cancer therapeutics market revenue, by Drug Class, 2016-2025 (USD Billion)
      • 10.6.4. The Middle East and Africa Lung cancer therapeutics market revenue, by End-User, 2016-2025 (USD Billion)
      • 10.6.5. The Middle East and Africa Lung cancer therapeutics market revenue, by Distribution Channel, 2016-2025 (USD Billion)
  •  
  • Chapter 11. Company Profile
    • 11.1. Hoffmann-La Roche
      • 11.1.1. Overview
      • 11.1.2. Financials
      • 11.1.3. Product Portfolio
      • 11.1.4. Business strategy
      • 11.1.5. Recent developments
    • 11.2. Eli Lilly and Company
      • 11.2.1. Overview
      • 11.2.2. Financials
      • 11.2.3. Product Portfolio
      • 11.2.4. Business strategy
      • 11.2.5. Recent developments
    • 11.3. Sanofi-Aventis
      • 11.3.1. Overview
      • 11.3.2. Financials
      • 11.3.3. Product Portfolio
      • 11.3.4. Business strategy
      • 11.3.5. Recent developments
    • 11.4. Pfizer
      • 11.4.1. Overview
      • 11.4.2. Financials
      • 11.4.3. Product Portfolio
      • 11.4.4. Business strategy
      • 11.4.5. Recent developments
    • 11.5. Celgene Corporation
      • 11.5.1. Overview
      • 11.5.2. Financials
      • 11.5.3. Product Portfolio
      • 11.5.4. Business strategy
      • 11.5.5. Recent developments
    • 11.6. GlaxoSmithKline
      • 11.6.1. Overview
      • 11.6.2. Financials
      • 11.6.3. Product Portfolio
      • 11.6.4. Business strategy
      • 11.6.5. Recent developments
    • 11.7. Boehringer Ingelheim
      • 11.7.1. Overview
      • 11.7.2. Financials
      • 11.7.3. Product Portfolio
      • 11.7.4. Business strategy
      • 11.7.5. Recent developments
    • 11.8. Agennix
      • 11.8.1. Overview
      • 11.8.2. Financials
      • 11.8.3. Product Portfolio
      • 11.8.4. Business strategy
      • 11.8.5. Recent developments
    • 11.9. AstraZeneca
      • 11.9.1. Overview
      • 11.9.2. Financials
      • 11.9.3. Product Portfolio
      • 11.9.4. Business strategy
      • 11.9.5. Recent developments
    • 11.10. Merck and company
      • 11.10.1. Overview
      • 11.10.2. Financials
      • 11.10.3. Product Portfolio
      • 11.10.4. Business strategy
      • 11.10.5. Recent developments

Methodology

Free Analysis

Cancer is a disease caused by an uncontrolled division of abnormal cells in part of the body. These extra cells slowly gather together to form a tissue mass called a tumor. It reduces the ability of lungs to supply oxygen to the bloodstream and lymphatic system. The leading cause of lung cancer is prolonged exposure to asbestos, cigarette, cigar, tobacco intake, pipe-smoking, exposer to pollution, and harmful radiations. The main symptoms of lung cancer are wheezing, coughing, chest pain, appetite loss, shortness of breath, and weight loss. Different therapies available for lung cancer include immunotherapy, vaccine therapy, radiation therapy, chemotherapy, and surgery.

The lung cancer therapeutics market is predicted grow substantially, owing to the growing number of people suffering from lung cancer, rising number of smokers, increasing exposure to asbestos, escalating demand for targeted therapies, presence of innovative and efficient drugs, and accelerating unhealthy lifestyle patterns. Additionally, the introduction of nano medication for lung cancer treatment is also driving the lung cancer therapeutics market globally. However, the high cost of drugs, negative effects of radiation therapies and chemotherapies, and poor cancer diagnostic facilities may limit the lung cancer therapeutics market.

Global Lung Cancer Therapeutics Market

The global lung cancer therapeutics market is fragmented based on cancer type, treatment, drug class, end-user, and distribution channel. Based on cancer type, the lung cancer therapeutics market includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). More than 85% of the lung cancers are found to be NSCLC. By treatment, the lung cancer therapeutics market includes immunotherapy, chemotherapy, targeted therapy, radiation therapy, and others. Based on drug class, the market is divided into multikinase inhibitors, EGFR inhibitors, alkylating agents, mitotic inhibitors, antimetabolites, and others. Antimetabolites are expected to show the highest CAGR in the future. Based on end-user, the lung cancer therapeutics market comprises hospitals, homecare, specialty clinics, and others. Based on distribution channel, the market for lung cancer therapeutics is categorized into retail pharmacy, hospital pharmacy, internet, and others.

North America will dominate the lung cancer therapeutics market over the forecast timeframe, owing to the increasing occurrences of lung cancer and rising geriatric population demanding therapeutics. Additionally, changing lifestyles and growing prevalence of smoking is leading to an escalating number of lung cancer incidences in North America. Europe is predicted to be the second-largest lung cancer therapeutics market, owing to the favorable government funding in the field of research, analysis and development of innovative medication, and technological growth related to cancer. The majority of the revenue of the Asia Pacific lung cancer therapeutics market is generated by the emerging nations of India and China, due to the growth in the number of smokers suffering from lung cancer.

Some of the key players in lung cancer therapeutics market include Hoffmann-La Roche, Eli Lilly and Company, Sanofi-Aventis, Pfizer, Celgene Corporation, GlaxoSmithKline Plc., Boehringer Ingelheim GmbH, Agennix AG, AstraZeneca Plc. and Merck & Co. among others.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com